Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X about a recent article he and Razelle Kurzrock authored:
“For your Sunday Reading, Pleased to share our Commentary published in Journal of Clinical Oncology, ASCO.
We explore The Paradigm Mismatch: Conventional Evidence Synthesis Versus ”
Title: Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review
Authors: Vivek Subbiah, Razelle Kurzrock
Read the Full Article in the Journal of Clinical Oncology.
Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared this post, adding:
“It is time to modernize. We cannot persist in prioritizing the evidence standards of the last century, when data was sparse. Share our commentary.”
More posts featuring Vivek Subbiah on OncoDaily.